WAYNE, Pa.--(BUSINESS WIRE)-- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/kg) is investigating potential claims against the board of directors of King Pharmaceuticals Inc. ("King Pharmaceuticals" or the "Company") (NYSE: KG) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell King Pharmaceuticals to Pfizer, Inc. in a transaction with a value of approximately $3.6 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of King Pharmaceuticals. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at [email protected] or visit: www.rmclasslaw.com/cases/kg.
Under the terms of the agreement, King Pharmaceuticals shareholders will receive $14.25 in cash for each share of King Pharmaceuticals common stock they hold.
If you own shares of King Pharmaceuticals and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/kg. You may also email Mr. Maniskas at [email protected]. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Pharmaceutical Professional Services Consulting Legal